Intersect ENT (XENT) Q1 Earnings & Revenues Miss Estimates
Orthofix Announces Appointment of Thomas A. West to Board of Directors
Why Is Intersect ENT (XENT) Down 0.6% Since Last Earnings Report?
Intersect ENT's (XENT) Sell-Off on Track Amid COVID Woes
MedTech Thrives on M&A Frenzy: 3 Stocks to Focus on
SHAREHOLDER ALERT: Monteverde & Associates PC Announces an Investigation of Intersect ENT, Inc. - XENT
ALERT: Rowley Law PLLC is Investigating Proposed Acquisition of Intersect ENT, Inc.
Intersect ENT (XENT) Q2 Loss Wider Than Expected, Revenues Top
Why Medtronic (MDT) Is Buying Intersect ENT For $1.1 Billion
SHAREHOLDER ALERT: WeissLaw LLP Investigates Intersect ENT, Inc.
Why Intersect ENT Shot 12% Higher on Friday
Intersect ENT Merger Investigation: Halper Sadeh LLP Announces Investigation Into Whether the Sale of Intersect ENT, Inc. Is Fair to Shareholders; Investors Are Encouraged to Contact the Firm – XENT
Shareholder Alert: Ademi LLP investigates whether Intersect ENT, Inc. has obtained a Fair Price in its transaction with Medtronic
Intersect ENT (XENT) Reports Q2 Loss, Tops Revenue Estimates
Medtronic Expands Its ENT Portfolio With Intersect ENT Acquisition For $28.25/Share
Intersect ENT Reports Second Quarter 2021 Financial Results
Medtronic to Acquire Intersect ENT
A Preview Of Intersect ENT's Earnings
Intersect ENT (XENT) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release
U.S Nationwide Commercial Availability of the VenSure™ Balloon Sinus Dilation System and Cube™ Navigation System Highlight Intersect ENT's Continued Commitment to Providing Innovative, Solutions for Patients with Chronic Rhinosinusitis
Intersect ENT Sees Q2 Sales Lag Wall Street Estimates; Raises $60M In Debt Funding
Intersect ENT to Report Second Quarter 2021 Financial Results on August 6
Intersect ENT to Report Second Quarter 2021 Financial Results on August 6
Intersect ENT (XENT) Surges 5.2%: Is This an Indication of Further Gains?
5 Probable MedTech Winners Post-COVID on Discounted PEG
Intersect ENT (XENT) Receives CE Mark for PROPEL Contour
Intersect ENT Receives CE Mark Approval for PROPEL® Contour for Patients with Chronic Rhinosinusitis Following Frontal Sinus Surgery
Intersect ENT (XENT) Q1 Loss Wider Than Expected, Revenues Top
Intersect ENT, Inc. (XENT) CEO Tom West on Q1 2021 Results - Earnings Call Transcript
Intersect ENT (XENT) Reports Q1 Loss, Tops Revenue Estimates
What's in Store for Intersect ENT's (XENT) Q1 Earnings?
Recap: Intersect ENT Q1 Earnings
Intersect ENT to Participate at Upcoming Investor Conferences
Intersect ENT Announces Date Change for First Quarter 2021 Financial Results Announcement
Intersect ENT to Report First Quarter 2021 Financial Results
Intersect ENT (XENT) Down 5.1% Since Last Earnings Report: Can It Rebound?
Intersect ENT Announces Changes to its Board of Directors
3 Beaten-Down MedTech Stocks to Scoop Up Amid the Pandemic
Intersect ENT (XENT) Hit by Low ENT Office Visits Amid COVID-19
New Strong Sell Stocks for March 17th
Intersect ENT (XENT) Q4 Loss Wider Than Expected, Revenues Top
Intersect ENT to Participate at the Oppenheimer 31st Annual Healthcare Conference
Intersect ENT, Inc. (XENT) CEO Tom West on Q4 2020 Results - Earnings Call Transcript
Intersect ENT Reports Fourth Quarter and Full Year 2020 Financial Results
A Preview Of Intersect ENT's Earnings
Why Earnings Season Could Be Great for Intersect ENT (XENT)
Intersect ENT to Report Fourth Quarter and Full Year 2020 Financial Results
Intersect ENT to Report Fourth Quarter and Full Year 2020 Financial Results
Intersect ENT Announces Launch of the New Straight Delivery System Packaged with the PROPEL® Mini Sinus Implant
Intersect ENT's (XENT) Q4 Preliminary Revenues Disappointing